Login to Your Account

Newlink touts IDO safety in phase II interim results

By Randy Osborne
Staff Writer

Tuesday, April 4, 2017

With clinical news pouring from pharma giants matching up the indoleamine 2,3-dioxygenase 1 (IDO1) blocker mechanism with PD-1 immune checkpoint inhibitors, Newlink Genetics Corp.'s interim results from NLG2103 seemed to take a back seat.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription